China's 3SBio To Pay U.S.$1.5 Million To Canada Firm To Develop Drug
This article was originally published in PharmAsia News
Executive Summary
China's 3SBio and Isotechnika Pharma of Canada signed a deal for the Chinese drug maker to develop voclosporin for preventing organ rejection in China, Hong Kong and Taiwan